.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
CLEAR Outcomes tested bempedoic acid in patients who were unable or unwilling to take guideline-recommended statin doses. Over a median follow-up of about 41 months, bempedoic acid lowered LDL cholesterol and reduced the risk of major cardiovascular events compared with placebo. The study is clinically useful because statin intolerance is a frequent reason for undertreatment of dyslipidemia. Bempedoic acid acts upstream of cholesterol synthesis in the liver and is activated predominantly in hepatic tissue, which may limit muscle-related adverse effects. For internists, the trial supports an evidence-based non-statin option when LDL cholesterol remains above target despite maximally tolerated therapy. Patient assessment should distinguish true statin-associated symptoms from nocebo effects, drug interactions or unrelated musculoskeletal conditions, because statins remain foundational therapy. When additional treatment is needed, selection should reflect absolute ASCVD risk, expected LDL reduction, cost, route of administration and patient preference.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
CLEAR Outcomes tested bempedoic acid in patients who were unable or unwilling to take guideline-recommended statin doses. Over a median follow-up of about 41 months, bempedoic acid lowered LDL cholesterol and reduced the risk of major cardiovascular events compared with placebo. The study is clinically useful because statin intolerance is a frequent reason for undertreatment of dyslipidemia. Bempedoic acid acts upstream of cholesterol synthesis in the liver and is activated predominantly in hepatic tissue, which may limit muscle-related adverse effects. For internists, the trial supports an evidence-based non-statin option when LDL cholesterol remains above target despite maximally tolerated therapy. Patient assessment should distinguish true statin-associated symptoms from nocebo effects, drug interactions or unrelated musculoskeletal conditions, because statins remain foundational therapy. When additional treatment is needed, selection should reflect absolute ASCVD risk, expected LDL reduction, cost, route of administration and patient preference.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
